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Genetic heterogeneity in ADHD: DAT1 gene only affects
probands without CD
Abstract
Previous studies have found heterogeneous association between DAT1-3'-UTR-VNTR and attention
deficit hyperactivity disorder (ADHD). Various proportions of conduct disorder (CD) comorbidity in
their ADHD samples may partially explain the observational discrepancies. Evidence for this comes
from family and twin studies which found ADHD probands with CD (ADHD + CD) are genetically
different from those without CD (ADHD - CD). Genotypes of 20 DAT1 markers were analyzed in 576
trios, consisting of 141 ADHD + CD and 435 ADHD - CD. In addition to the classical TDT test, a
specific genetic heterogeneity test was performed to identify variants that have different transmission
patterns in the two phenotypic subgroups. After multiple-test correction, rs40184 and rs2652511 were
significant in TDT tests. Further heterogeneity test found the two SNPs had a significant transmission
pattern difference between ADHD + CD and ADHD - CD children, indicating that DAT1 has a
significantly greater genetic influence on ADHD without CD. Although the result needs further
replications, it does highlight the importance of selecting genetically homogeneous samples for
molecular genetic analyses of ADHD. (c) 2007 Wiley-Liss, Inc.
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Previous studies have found heterogeneous asso-
ciation between DAT1-30-UTR-VNTR and atten-
tion deficit hyperactivity disorder (ADHD).
Various proportions of conduct disorder (CD)
comorbidity in their ADHD samples may partially
explain the observational discrepancies. Evi-
dence for this comes from family and twin studies
which found ADHD probands with CD (ADHDþ
CD) are genetically different from those without
CD (ADHDCD). Genotypes of 20 DAT1 markers
were analyzed in 576 trios, consisting of 141
ADHDþCD and 435 ADHDCD. In addition to
the classical TDT test, a specific genetic hetero-
geneity test was performed to identify variants
that have different transmission patterns in the
two phenotypic subgroups. After multiple-test
correction, rs40184 and rs2652511 were signifi-
cant in TDT tests. Further heterogeneity test
found the two SNPs had a significant transmission
pattern difference between ADHDþCD and
ADHDCD children, indicating that DAT1 has a
significantly greater genetic influence on ADHD
without CD. Although the result needs further
replications, it does highlight the importance
of selecting genetically homogeneous samples
for molecular genetic analyses of ADHD.
 2007 Wiley-Liss, Inc.
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INTRODUCTION
Family, twin, and adoption studies have consistently shown
that attention deficit hyperactivity disorder (ADHD) is highly
heritable (>75%) with population prevalence estimated at 4–
8% [Asherson, 2004; Heiser et al., 2004; Faraone et al., 2005;
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Thapar et al., 2005; Waldman and Gizer, 2006]. However, there
remains considerable uncertainty about the more specific
etiology of ADHD. The rationale for early efforts to identify
ADHD susceptibility genes using candidate gene approaches
were largely guided by the fact that ADHD children responded
favorably to stimulants such as methylphenidate and dexam-
phetamine [Spencer et al., 1996]. Based on the fact that these
medications inhibit the dopamine transporter, the dopamine
transporter gene (DAT1 or SLC6A3) became a target of
investigation [Cook et al., 1995]. During the last decade, mixed
positive and negative findings emerged from a large number of
independent studies exploring the association between DAT1
and ADHD. The most intensively tested marker, a 40-bp
variable number of tandem repeat (VNTR) located in the
30-untranslated region (30-UTR) was shown to have a small
(OR¼ 1.13, 95% CI (1.03–1.31)) but significant effect in a meta-
analysis that pooled family based studies together [Faraone
et al., 2005]. More recently, however, a further meta-analysis
of DAT1 that included a more comprehensive analysis of
available studies, found no overall evidence for association but
significant evidence of heterogeneity between datasets [Li
et al., 2006]. The reason for the observed heterogeneity is
currently unknown.
One possible explanation for such heterogeneity is that the
40-bp VNTR is not the functional variant causing suscepti-
bility and may tag one or more causal variants to different
degrees from sample to sample. Evidence for this comes from
the analysis of an additional 30-bp VNTR in intron 8 that
showed association of ADHD to a specific haplotype of the two
VNTR markers in UK and Taiwanese samples, as well as
the IMAGE project sample (pooled OR¼ 1.4, P¼ 6 107)
[Asherson et al., 2007]. The low resolution obtained by using
only one marker may partially explain the inconsistent find-
ings. Another possible source of inter-study heterogeneity is of
a phenotypic nature. Like other psychiatric disorders, ADHD
shows substantial phenotypic heterogeneity associated with
different DSM-IV subtypes [Faraone et al., 2000a], the co-
existence of various comorbid traits [Thapar et al., 2006], as
well as variability in the persistence of symptoms across the
lifespan [Faraone and Tsuang, 2001; Faraone et al., 2006].
Some of this heterogeneity is likely to have its origin in genetic
differences between individuals [Faraone et al., 2000c]. In the
current article, we set out to test whether the pattern of inter-
study variability in the ADHD–DAT1 association might be
explained, at least in part, by heterogeneity within ADHD
samples in relation to comorbid conduct disorder (CD).
The comorbidity between ADHD and CD has been observed
consistently for many years. Taylor noted that the co-morbidity
between ADHD and CD raises a key nosological question: are
these two disorders best seen as co-occurring yet separate
entities, or does their consistent co-occurrence signal the
presence of a separate category of one or other of the disorders
[Taylor, 1994]? The former approach was taken by the DSM-IV
[Amercian Society of Psychiatry, 1994], whereas the latter has
been recognized with the separate category of hyperkinetic CD
used by the ICD-10 [World Health Organization, 1988]. To
address this issue from a genetic epidemiologic perspective,
Faraone and colleagues showed in several independent
samples that the pattern of familial co-aggregation of DSM-
defined ADHD and CD was consistent with the ICD-10
formulation of hyperkinetic CD as a discrete familial subtype
[Faraone et al., 1995, 1998, 2000b, 2000c]. Data from other
groups also favored a familial distinction between ADHD with
CD (ADHDþCD) and other ADHD children (ADHDCD).
Lahey [1988] reported higher rates of antisocial disorders,
depression, and substance abuse among relatives of ADHDþ
CD probands compared to ADHDCD probands. Mothers of
ADHDþCD children have also been found to have higher rates
of psychopathology than the mothers of ADHDCD children
[Lahey et al., 1989]. Parents of ADHDþCD children have
been found to have higher rates of retrospectively reported
childhood hyperactivity, CD, and substance use than parents
of ADHDCD children [Frick et al., 1991]. Together these
findings indicate an increased familial co-segregation of
the ADHDþCD phenotype; although they do not exclude the
possibility of shared environmental effects on the familial co-
transmission of CD with ADHD. Twin studies confirmed the
familial co-aggregation of ADHD and CD [Szatmari et al.,
1993; Silberg et al., 1996] and found that the genes influencing
conduct problems were all shared with those effecting ADHD
symptoms [Thapar et al., 2001]. These studies also showed the
existence of some genetic effects that were unique to ADHD, as
well as shared environmental effects on the risk for conduct
problems but not ADHD. In recent psychophysiological studies
of event-related potentials and task performance, the
ADHDþCD group was found to be psychophysiologically less
deviant or impaired than either pure ADHD group or pure CD
group indicating that ADHDþCD might represent a separate
disorder distinct from ADHDCD [Banaschewski et al., 2003;
Albrecht et al., 2005].
Driven by these compelling data, we hypothesize that
comorbidity with CD partially accounts for the inter-study
variability in the ADHD–DAT1 association. In the current
study, we set out to test this hypothesis by reanalyzing data
from a previous candidate gene analysis utilizing data from the
IMAGE project which provided nominal association evidence
at the DAT1 locus [Brookes et al., 2006].
MATERIALS AND METHODS
Subjects and Genotyping
In this study, we used data from our previous analysis of
51 candidate genes in which the association with DAT1
reached gene-wide significance and suggested the existence
of two independent associations at the 30- and 50-ends of
the gene [Brookes et al., 2006]. The original nuclear family
sample was stratified into independent ADHDþCD and
ADHDCD trios. This allowed us to formally carry out a
standard chi-square test of genetic heterogeneity based on the
transmission patterns in both groups.
European Caucasian subjects were recruited from 12 specia-
list clinics in eight countries: Belgium, Germany, Holland,
Ireland, Israel, Spain, Switzerland, and United Kingdom.
Ethical approval for the study was obtained from National
Institute of Health registered ethical review boards for each
center. All ADHD probands and their siblings were aged 5 to
17 at the time of entry into the study and access was required
to one or both biological parents for DNA collection. Entry
criteria for probands were a clinical diagnosis of DSM-IV
combined subtype ADHD and having one or more full siblings
available for ascertainment of clinical information and DNA
collection. Exclusion criteria applying to both probands and
siblings included autism, epilepsy, IQ< 70, brain disorders,
and any genetic or medical disorder associated with external-
izing behaviors that might mimic ADHD. For the analyses
completed here, we selected the subset of 576 proband–parent
trios for whom we had complete genotype data for markers
across the DAT1 gene.
The research diagnosis of DSM-IV ADHD and CD was
reached following completion of a parent interview with the
parent account childhood symptoms (PACS) [Taylor et al.,
1986]. This is a semi-structured, standardized, investigator-
based interview developed as an instrument to provide an
objective measure of child behavior. For the diagnosis of
ADHD, a standardized algorithm was applied to PACS data to
derive each of the 18 DSM-IV ADHD items, providing opera-
tional definitions for each behavioral symptom. These were
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then combined with items that scored 2 or 3 from the teacher
rated Conners’ ADHD subscale, to generate the total number of
items from the DSM-IV symptom checklist. The definition of
situational pervasiveness required that some symptoms
occurred within two or more different situations from the
PACS interview, or the presence of one or more symptoms
scoring 2 or more from the ADHD subscale of the teacher rated
Conners. The diagnosis of DSM-IV CD was based on the PACS
data alone. All the CD diagnosis was made without the
existence of oppositional defiant disorder (ODD). Of the 576
probands included in this analysis, 435 were diagnosed
without CD (ADHDCD) and 141 with CD (ADHDþCD).
As shown in Table I, there is no significant age or sex difference
between the two phenotypic subgroups. Table II describes the
demographic distribution of the 576 trios. The ADHDþCD
proband incidence rates are between 9 and 45% across our
study sites. Using Pearson’s chi-squared test of equal incidence
across centers, we found the incidence rates significantly
different between IMAGE centers through 10,000 simulations
(P¼ 0.0002), suggesting a high degree of inter-site phenotypic
heterogeneity in terms of CD.
We selected 18 common SNPs (minor allele frequency> 0.05)
that had been successfully genotyped at the DAT1 locus in the
original study. Genotypes from two VNTR markers including
the most intensively investigated 30-UTR 40-bp VNTR and the
intron 8 30-bp VNTR were also included in this analysis
[Asherson et al., 2007].
Statistical Tests
The Transmission Disequilibrium Test (TDT) was used to
test for single marker associations [Ewens and Spielman,
2005]. For haplotype-specific TDT, the haplotype counts were
obtained by summing the EM-estimated fractional likelihoods
of each individual as implemented in Haploview [Barrett et al.,
2005]. In addition, we used ETDT to test the multi-allele hap-
lotype transmission disequilibrium [Sham and Curtis, 1995].
All the association tests were performed in each phenotypic
subgroup separately and then in the full sample.
To detect genetic heterogeneity between the two subgroups,
we used a standard chi-square test. Under the null hypothesis
of no genetic heterogeneity, a variant is expected to have the
same effect in both clinical subgroups, so that an allele of the
marker will be expected to have the same transmission to non-
transmission ratio (T/NT) from heterozygotic parents in each
phenotypic subgroup. Thus, we counted the observed numbers
of a particular allele transmitted and non-transmitted from
heterozygotic parents to affected children in each subgroup as
shown in the following 2 2 contingency table.
Our test statistic was defined as:
w2 ¼
X
ij
ðOij  EijÞ2
Eij
¼ ðad  bcÞ
2ða þ b þ cþ dÞ
ðaþ bÞðcþ dÞðb þ dÞða þ cÞ
where Oij denotes the observed counts of the alleles in each cell
and Eij denotes the expected counts of the alleles in each
cell under the null hypothesis. The i denotes two subgroups
(1¼ADHDþCD, 2¼ADHD CD) and j denotes whether the
allele is transmitted (1¼ transmitted, 2¼non-transmitted).
The a, b, c, and d are the observed cell counts. Significance level
was evaluated against w2 distribution with 1 degree of freedom.
A significant test statistic would support the alternative
hypothesis that transmission patterns of this allele are
significantly different between the two subgroups. In other
words, the marker has significantly different genetic effect on
the two subgroups. When the test is used for SNPs, the statistic
is the same for two alleles because their transmissions are
mutually exclusive. For the two VNTRs, we reported the test
statistics for the previously identified 10R (for the VNTR in the
30-UTR) and 3R (for the VNTR in intron 8) alleles [Asherson
et al., 2007].
RESULTS
Single Marker Association Analysis
The 18 SNP and two VNTR markers analyzed here covered
the whole DAT1 genomic region with an average density of
1 marker/2.85 kb. Figure 1 shows the pairwise linkage dis-
equilibrium (LD) measure D0 in the founders as estimated by
GOLD [Abecasis and Cookson, 2000]. The three-block struc-
ture pattern is consistent with that identified in a recent com-
prehensive study of the DAT1 genomic region [Greenwood
et al., 2006]. Both VNTR markers fall into the 30-end block with
the 40-bp VNTR in tight LD with other SNPs and the 30-bp
VNTR at the boundary of this block. This pattern suggests that
the previous association studies using these two VNTRs can
only pick up association signals from the 30-end of the DAT1
locus.
Table III summarizes the single marker TDT test results in
each phenotypic subgroup and the full sample. The two VNTRs
only showed marginal associations (P< 0.1) in both the
ADHDCD group and the full sample. Five SNPs (rs40184,
rs2652511, rs11564750, rs10070282, rs2550946) showed nom-
inally significant (P< 0.05) associations in both the ADHD
CD group and the full sample. In particular, rs40184 (P¼
0.0004) from the 30-end LD block in DAT1 and rs2652511
(P¼ 0.002) from the 50-end LD block were still significant in the
ADHDCD group after the stringent Bonferroni multiple test
correction (P< 0.0025). More importantly, because these two
SNPs locate in separate LD blocks with D0 ¼ 0.15 between them
(95% CI: 0.09–0.2), we can view them as independent
association signals at the DAT1 locus. Strikingly, none of the
markers showed any association signal within the ADHDþCD
group.
Single Marker Genetic Heterogeneity Test
The genetic heterogeneity tests between ADHDþCD and
ADHDCD are also summarized in Table III. The two
significant SNPs (rs40184, rs2652511) from the association
test in the ADHDCD group also showed significant genetic
heterogeneity between groups (P¼ 0.016 and P¼ 0.023). In
addition, rs27072 showed significant heterogeneity (P¼
0.034), but has only a marginal association with the ADHD
CD group (P¼ 0.06) and no association with the ADHDþCD
group (P¼ 0.168). Owing to the multiple LD block structures
at the DAT1 locus and the heterogeneity signals seen in the
two blocks, we opted to perform simulations to estimate the
statistical significance of observing two such independent
signals. In each simulation, only the proband diagnosis was
permuted to preserve the LD structure. The heterogeneity test
was performed on each permuted data set and the highest
statistic from each LD block was collected. From 10,000
simulations, 181 were observed with multiple significant
heterogeneity signals (P< 0.05) from different LD blocks,
simultaneously. Thus the empirical significance of our finding
is P¼ 0.018.
ADHDþCD ADHDCD
Transmitted a b
Non-transmitted c d
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Haplotype Analysis
Table IV presents haplotype-specific TDT tests of the two
significant SNPs (rs40184, rs2652511) in both subgroups, and
the heterogeneity test. As expected, all four haplotype-specific
TDT tests were non-significant in the ADHDþCD subgroup
(P> 0.1). On the contrary, the most common GG haplotype
(35.3%) is significantly over-transmitted in the ADHDCD
group (haplotype specific P¼ 1.6 106). The AA haplotype
showed a moderate protective effect. In a 3-df likelihood test of
transmission disequilibrium, the two locus haplotype trans-
mission is significantly distorted in the ADHDCD group
(P¼ 8.5 105). Finally, the transmission patterns of the GG
haplotype were significantly different (P¼ 0.0009) in the chi-
square test of genetic heterogeneity between the two sub-
groups. This was due to significant over-transmission in the
ADHDCD subgroup and non-significant under-transmis-
sion in the ADHDþCD subgroup.
DISCUSSION
In this study, TDT tests in ADHDþCD and ADHDCD
subgroups gave very different results. Two SNPs (rs40184 and
rs2652511) from the DAT1 gene were significantly associated
with ADHDCD after the application of the stringent
Bonferroni correction for multiple tests. In the haplotype-
specific TDT test at these two loci, a highly significant
(P¼ 1.6 106) association was observed between the GG
haplotype and the ADHDCD phenotype. In contrast, none of
the 20 markers were associated with ADHDþCD even without
correction. When the two phenotypic subgroups were com-
bined, there were only nominally significant signals, but none
of them remained after multiple test correction. One potential
explanation for this observational contrast is age or gender
difference between the subgroups. However, as shown in
Table I, neither age nor sex is significantly different between
the two subgroups. Another possible explanation might be the
genetic mechanisms associated with varying levels of comorbid
CD across samples. We applied a formal statistical test to
address whether observing the different association results in
ADHDþCD and ADHDCD was due to genetic heterogeneity
or simply occurred by chance. The test statistic was calculated
with heterozygous parents’ allele T/NT to ensure it was robust
for population stratification. Our single marker genetic
heterogeneity tests identified significant SNPs in two LD
blocks at the DAT1 locus. Further permutation results
suggested the chance of observing such a pattern of genetic
heterogeneity under the LD background as being very low
(P¼ 0.018). Thus, we are confident that the significance of the
subgroup difference in the transmission pattern really indexes
the impact of phenotypic heterogeneity. Considering the fact
that a significant association was only found within the
ADHDCD subgroup, our data may further indicate that
variation in DAT1 is only implicated in the genetic etiology of
ADHD children who do not have CD.
Rather than an allele frequency-based pseudo case-control
test, we preferred to use a T/NT ratio-based test statistic in our
heterogeneity test in this study because potential population
stratification is a potential concern in the IMAGE multi-
country sample [Neale et al., 2007]. Population stratification
may lead to different allele frequencies in subgroups and
produce either false positive or false negative results in case-
control studies. For example, in the haplotype analysis shown
in Table IV, our T/NT ratio-based test demonstrated significant
(P¼ 0.0009) heterogeneity in the transmission of GG haplo-
type. However, using a pseudo case-control mannered test to
compare allele frequency between the two subgroups would
have found no significant difference and produced a false
negative result. Thus, our data provided an example of taking
advantage of a family based study design to avoid the potential
bias associated with population stratification.
The findings in this report may also shed some light on the
debate over whether ADHDþCD is quantitatively or qual-
itatively different from ADHDCD in its genetic etiology. The
TABLE II. Sample Demographic Distribution
Study site
#
ADHDCD
#
ADHDþCD Full sample
ADHDþCD
incidence
rate (%)
Site 1 45 20 65 31
Site 2 20 5 25 20
Site 3 63 13 76 17
Site 4 13 8 21 38
Site 5 16 5 21 24
Site 6a 41 33 74 45
Site 7 20 2 22 9
Site 8 51 23 74 31
Site 9 35 13 48 27
Site 10 87 14 101 14
Site 11 44 5 49 10
Total 435 141 576 24
aTwo study sites from UK were merged because one of them has only a few families.
TABLE I. Age and Sex Distribution in the Two Subgroups
ADHDþCD ADHDCD P-valuea
Age 10.86 2.88 10.912.70 0.87
Sex (male:female) 128:13 374:61 0.12
# DSM-IV symptoms 16.38 1.38 16.751.25 0.003
aBoth tests were performed with functions in R statistical package. Significance for age and number of DSM-IV
ADHD symptom difference was from the standard t-test function t.test. Significance for sex difference was from the
equal proportion test function prop.test.
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quantitative theory has its origins in twin model fitting results
that suggest a liability threshold model in which genetic factors
associated with CD are entirely shared by ADHD and ADHDþ
CD is a genetically more severe form of ADHD [Thapar et al.,
2001]. According to this view, the same set of causal genes
determines both phenotypes but has stronger effects on the
ADHDþCD subgroup. On the other hand, key evidence
supporting the qualitative theory comes from familial studies
showing that relatives of ADHDCD children have a similar
risk for CD as relatives of normal controls [Faraone et al., 1998,
2000c]. From this perspective, it is reasonable to infer at the
molecular level, that ADHDþCD genes do not have to confer
risk for ADHDCD or vice versa. In the current study, we
tested gene effects in both subgroups and found DAT1
conferring a significant risk for ADHDCD but a non-
significant protective effect for ADHDþCD. This result does
not support the liability threshold model, which predicts a gene
having unidirectional effects on both groups, but is fully
compatible with the prediction of the qualitative theory, which
suggests DAT1 as a potential ADHDCD-specific gene.
A few studies have reported post hoc association tests with
dopamine genes in ADHDþCD children after having non-
significant results with the full ADHD sample. Two earlier
studies did find DRD4 was only associated in ADHD children
with conduct problems [Holmes et al., 2002; Kirley et al., 2003].
Another recent cohort study found no association between
DRD4 and ADHDþCD [Mill et al., 2006]. However, none of
them reported association tests in the ADHDCD subgroup
because they all had an a priori hypothesis that genes
conferring risk for ADHDCD would also affect ADHDþCD
with bigger effect size. Moreover, there was no statistical
evidence in these studies indicating DRD4 to have more
influence on ADHDþCD because the ADHDCD subgroup
has been ignored in their secondary analysis. Therefore, it
is questionable that the significant observations in the
ADHDþCD groups of the aforementioned studies were simply
due to random allelic fluctuations when the original sample
TABLE III. Single Marker TDT Test and Heterogeneity Test for 18 Common SNPs and Two VNTRs at the DAT1 Locus
Marker Allele 1 Allele 2 Position MAF
TDT test P-values Likelihood ratio test of heterogeneity
ADHDCD ADHDþCD
Full
sample
ADHDCD ADHDþCD
w2-PT NT T NT
rs7732456 A C 1445965 0.0656 0.2167 0.1137 0.0722 62 49 17 9 0.3722
40bp-VNTR 10R 9R 1447327 — 0.0602 0.6985 0.0664 191 156 54 50 0.5756
rs27072 A G 1447522 0.1577 0.0604 0.1678 0.3380 105 134 44 32 0.0337
rs1042098 A G 1447815 0.2809 0.0997 0.4369 0.0691 193 162 57 49 0.9146
rs40184a A G 1448077 0.4420 0.0004 0.5376 0.0054 173 245 68 61 0.0239
rs6869645 A G 1457548 0.0627 0.7738 0.8474 0.7316 53 56 13 14 0.9643
30bp-VNTR 3R 2R 1464634 — 0.0693 1.0000 0.0997 161 130 32 32 0.5982
rs11564758 C G 1473588 0.3960 0.1494 0.5838 0.3154 188 217 63 57 0.2417
rs464049 A G 1476905 0.4351 0.5962 0.8586 0.7029 221 210 62 64 0.6827
rs463379 C G 1484164 0.2222 0.7282 0.3120 0.8407 152 146 44 54 0.2937
rs460000 A C 1485825 0.2220 0.7725 0.3169 0.8023 152 147 45 55 0.3119
rs403636 A C 1491354 0.1688 0.2451 0.6275 0.4250 111 129 36 32 0.3297
rs13189021 A G 1495842 0.2305 0.2717 0.2201 0.7247 159 140 42 54 0.1077
rs6350 A G 1496199 0.0657 0.9215 0.8618 1.0000 52 51 16 17 0.8415
rs2652511a A G 1499389 0.4100 0.0020 0.2847 0.0276 184 248 69 57 0.0160
rs11564751 A G 1500223 0.0714 0.5101 0.8658 0.5107 53 60 17 18 0.8629
rs11564750 C G 1500762 0.0900 0.0226 0.2064 0.0092 57 84 21 30 0.9257
rs3756450 A G 1501148 0.1211 0.2159 0.7855 0.2227 103 86 28 26 0.7311
rs10070282 A G 1503444 0.4199 0.0038 0.5407 0.0254 246 186 62 69 0.0532
rs2550946 A G 1503513 0.4201 0.0027 0.7237 0.0140 184 246 66 62 0.0804
The position of the variants is based on NCBI assembly 35. Minor Allele Frequency (MAF) is based on founder genotypes. ADHDþCD indicates the ADHD
comorbid with CD group, ADHDCD indicates the ADHD only group. Both TDT and heterogeneity tests were based on allele 1. Nominal significant
P-values are marked in bold. The numbers of transmitted and non-transmitted allele 1 in each subgroup are also provided to differentiate the risk alleles in
each subgroup. The markers can be divided into three LD blocks as separated by solid lines.
aSNPs rs2652511 and rs40184 were used in the haplotype analysis.
Fig. 1. Linkage disequilibrium pattern and block structure at DAT1
locus. The diagram was plotted on the D’ scale estimated from the founders.
The two circled SNPs, rs40184 and rs2652511 were used in our haplotype
analysis. LD between them is D’¼0.159 with 95% CI (0.1–0.21).
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was subdivided. In the current study, both ADHDþCD and
ADHDCD subgroups were used in the heterogeneity test. It
is the comparison between them that provided the statistical
evidence indicating DAT1 as a potential ADHDCD-specific
gene. This result suggests that the ADHDCD subgroup is
equally important to the ADHDþCD subgroup in terms of
mapping genes underlying ADHD genetic heterogeneity and
should not be precluded.
More generally, our findings highlight the importance of
establishing genetically homogeneous samples for ADHD
molecular genetic studies. In this study, we stratified our
ADHD sample based on the prior knowledge that ADHDþCD
may have a different genetic etiology compared to ADHDCD.
Our results do suggest that strong ADHD–DAT1 associations
can only be detected with the ADHDCD subgroup sample.
Similarly, other phenotypic features such as DSM-IV subtype
and symptom persistence may also be determined by genetic
difference to some extent [Faraone et al., 2000c; Thapar et al.,
2006]. As shown by some association studies, DAT1 and DRD5
have stronger effects on the development of inattentive sub-
type symptoms [Waldman et al., 1998; Lowe et al., 2004]. These
results suggest that investigating specific phenotype sub-
groups may help to dissect the molecular genetic basis of
ADHD. The main difficulty of using such stratified subgroup
designs is the recruitment burden to get sufficient statistical
power. For example, only about a quarter of the total ADHD
sample in the current study also had CD. There will be little or
no extra power to detect ADHDþCD associations with only a
quarter of the total sample, unless the gene effect is specific to
ADHDþCD or contributes a significantly higher risk to
ADHDþCD. Nevertheless, with the rapid growth of large-
scale international cooperation in ADHD molecular studies, we
will be able to achieve sizable phenotypically homogeneous
samples and test specific hypotheses with them.
In summary, the genetic heterogeneity test in this study
found that variations in the DAT1 gene confer significantly
different risks to ADHD children with and without CD.
Combined with the association findings in each subgroup, we
found that DAT1 was only associated with ADHD children
without CD. This result may partially explain the observa-
tional inter-study heterogeneity in previous ADHD–DAT1
associations. It also highlights the importance of using
genetically homogeneous samples in ADHD molecular genetic
studies. Given the presence of significant CD incidence rate
difference among our recruiting sites and the large amount of
statistical tests performed in the current investigation, we
believe further replications are needed to confirm the above
conclusions [Sullivan, 2007].
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